eXIthera Pharmaceuticals is a clinical stage biotech company focused on discovering and developing Factor XIa inhibitors for the prevention of stroke and thrombosis.
eXIthera’s stroke prevention and antithrombosis drugs are based on the unique pathophysiological role of Factor XI in the initiation of intravascular thrombi without causing undue bleeding. eXIthera’s drug candidates are small molecules that are highly potent, rapid-onset, and selective Factor XIa inhibitors.  Experiments conducted by eXIthera to date with these compounds provide evidence of safety and antithrombotic efficacy.